To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effectiveness trials: critical data to help understand how respiratory medicines really work?
GSK Nordic Cluster, GSK, Solna, Sweden.
Örebro University, School of Medical Sciences. Department of Respiratory Medicine.ORCID iD: 0000-0003-1926-8464
Department of Clinical Sciences Lund, Respiratory Medicine and Allergology, Lund University, Lund, Sweden.
Department of Medical Sciences: Respiratory, Allergy & Sleep Research, Uppsala University, Uppsala, Sweden.
2019 (English)In: European Clinical Respiratory Journal, ISSN 2001-8525, Vol. 6, no 1, article id 1565804Article, review/survey (Refereed) Published
Abstract [en]

Most of the information about the benefits, safety aspects, and cost effectiveness of pharmacological treatment in the respiratory field has been obtained from traditional efficacy studies, such as randomised controlled trials (RCT). The highly controlled environment of an RCT does not always reflect everyday practice. The collection, analysis, and application of effectiveness data to generate Real World Evidence (RWE) through pragmatic trials or observational studies therefore has the potential to improve decision making by regulators, payers, and clinicians. Despite calls for more RWE, effectiveness data are not widely used in decision making in the respiratory field. Recent advances in data capture, curation, and storage combined with new analytical tools have now made it feasible for effectiveness data to become routine sources of evidence to supplement traditional efficacy data. In this paper, we will examine some of the current data gaps, diverse types of effectiveness data, look at proposed frameworks for the positioning of effectiveness data, as well as provide examples from therapeutic areas. We will give examples of both previous effectiveness studies and studies that are ongoing within the respiratory field. Effectiveness data hold the potential to address several evidentiary gaps related to the effectiveness, safety, and value of treatments in patients with respiratory diseases.

Place, publisher, year, edition, pages
Taylor & Francis Group, 2019. Vol. 6, no 1, article id 1565804
Keywords [en]
Effectiveness, real-world evidence, pragmatic trials, evidence-base, efficacy RCT, levels of evidence, respiratory disease, asthma, COPD, co-morbidity
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:oru:diva-72437DOI: 10.1080/20018525.2019.1565804ISI: 000457088000001PubMedID: 30728925Scopus ID: 2-s2.0-85070876148OAI: oai:DiVA.org:oru-72437DiVA, id: diva2:1288722
Available from: 2019-02-14 Created: 2019-02-14 Last updated: 2024-01-02Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Sundh, Josefin

Search in DiVA

By author/editor
Sundh, Josefin
By organisation
School of Medical Sciences
In the same journal
European Clinical Respiratory Journal
Respiratory Medicine and Allergy

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 322 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf